homepage-top-section

The FDA will review the NDA for KPI-121 0.25%, which is designed to provide temporary relief to the signs and symptoms of dry eye disease, including dry eye

Indian pharmaceutical company Lupin has awarded the licensing rights of its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) programme to AbbVie. The deal gives AbbVie exclusive global

CellforCure is a major French contract development and manufacturing organization engaged in the production of cell and gene therapies in Europe. As per terms of the deal, Novartis

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor,

The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs. In 2017, AstraZeneca

Based in Waltham of Massachusetts, Tesaro is a commercial-stage firm engaged in the development of advanced therapies to treat cancer. As per the terms of the deal, GSK’s

Truxima, a monoclonal antibody (mAb), has been approved to treat adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL) as a single agent.

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CEO

The company has randomized the first patient of the mid-stage trial which will assess the efficacy and safety of Blautix in patients having IBS with constipation (IBS-C) and/or